Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists

Human Immunology

Volumn 70, Issue 5, 2009, Pages 345-352

  Adorini, Luciano ^a   Penna, Giuseppe ^a  

^a INTERCEPT PHARMACEUTICALS   (United States)

Author keywords

1,25(OH)2D3; CD4+CD25+ regulatory T cells; Tolerogenic DCs

Indexed keywords

15 DEOXYSPERGUALIN; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; BUTYRIC ACID; BXL 219; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CHEMOKINE; CYCLOSPORIN A; EVEROLIMUS; GLUCOCORTICOID; I KAPPA B; IMMUNOMODULATING AGENT; MOMETASONE FUROATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFLUMIC ACID; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR AGONIST;

ADAPTIVE IMMUNITY; ALLOIMMUNITY; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW CELL; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL MATURATION; CELLULAR DISTRIBUTION; COLITIS; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; GRAFT REJECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION TOLERANCE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CALCITRIOL; CYTOKINES; DENDRITIC CELLS; DERMATOLOGIC AGENTS; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC FACTORS; INFLAMMATION; RECEPTORS, CALCITRIOL; T-LYMPHOCYTES, REGULATORY;

EID: 65049086842     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2009.01.016     Document Type: Article

References (128)

1. Steinman R.M., and Banchereau J. Taking dendritic cells into medicine. Nature 449 (2007) 419-427
2. Shortman K., and Liu Y.J. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2 (2002) 151-156
3. Colonna M., Trinchieri G., and Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat Immunol 5 (2004) 1219-1228
4. Liu Y.J. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23 (2005) 275-306
5. Shevach E.M., DiPaolo R.A., Andersson J., Zhao D.M., Stephens G.L., and Thornton A.M. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol Rev 212 (2006) 60-73
6. Vignali D.A., Collison L.W., and Workman C.J. How regulatory T cells work. Nat Rev Immunol 8 (2008) 523-532
7. Miyara M., and Sakaguchi S. Natural regulatory T cells: Mechanisms of suppression. Trends Mol Med 13 (2007) 108-116
8. Raimondi G., Turner M.S., Thomson A.W., and Morel P.A. Naturally occurring regulatory T cells: Recent insights in health and disease. Crit Rev Immunol 27 (2007) 61-95
9. Baecher-Allan C., and Hafler D.A. Human regulatory T cells and their role in autoimmune disease. Immunol Rev 212 (2006) 203-216
10. Roncarolo M.G., and Battaglia M. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 7 (2007) 585-598
11. Mahnke K., Schmitt E., Bonifaz L., Enk A.H., and Jonuleit H. Immature, but not inactive: The tolerogenic function of immature dendritic cells. Immunol Cell Biol 80 (2002) 477-483
12. Yamazaki S., Iyoda T., Tarbell K., Olson K., Velinzon K., Inaba K., and Steinman R.M. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198 (2003) 235-247
13. Lutz M.B., and Schuler G. Immature, semi-mature and fully mature dendritic cells: Which signals induce tolerance or immunity?. Trends Immunol 23 (2002) 445-449
14. Adler H.S., and Steinbrink K. Tolerogenic dendritic cells in health and disease: Friend and foe!. Eur J Dermatol 17 (2007) 476-491
15. Steinman R.M., Hawiger D., and Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 21 (2003) 685-711
16. Belkaid Y., and Oldenhove G. Tuning microenvironments: Induction of regulatory T cells by dendritic cells. Immunity 29 (2008) 362-371
17. Puccetti P., and Grohmann U. IDO and regulatory T cells: A role for reverse signalling and non-canonical NF-kappaB activation. Nat Rev Immunol 7 (2007) 817-823
18. Colonna M., Nakajima H., and Cella M. A family of inhibitory and activating Ig-like receptors that modulate function of lymphoid and myeloid cells. Semin Immunol 12 (2000) 121-127
19. Delgado M., Gonzalez-Rey E., and Ganea D. Vasoactive intestinal peptide: The dendritic cell→regulatory T cell axis. Ann N Y Acad Sci 1070 (2006) 233-238
20. Rutella S., Bonanno G., Procoli A., Mariotti A., de Ritis D.G., Curti A., et al. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood 108 (2006) 218-227
21. Wakkach A., Fournier N., Brun V., Breittmayer J.P., Cottrez F., and Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18 (2003) 605-617
22. Giuliani M., Giron-Michel J., Negrini S., Vacca P., Durali D., Caignard A., et al. Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS ONE 3 (2008) e2241
23. Watanabe N., Wang Y.H., Lee H.K., Ito T., Wang Y.H., Cao W., and Liu Y.J. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 436 (2005) 1181-1185
24. Mahnke K., Johnson T.S., Ring S., and Enk A.H. Tolerogenic dendritic cells and regulatory T cells: A two-way relationship. J Dermatol Sci 46 (2007) 159-167
25. Houot R., Perrot I., Garcia E., Durand I., and Lebecque S. Human CD4+CD25 high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 176 (2006) 5293-5298
26. Veldhoen M., Moncrieffe H., Hocking R.J., Atkins C.J., and Stockinger B. Modulation of dendritic cell function by naive and regulatory CD4+ T cells. J Immunol 176 (2006) 6202-6210
27. Kryczek I., Wei S., Zou L., Zhu G., Mottram P., Xu H., et al. Cutting edge: Induction of B7-H4 on APCs through IL-10: Novel suppressive mode for regulatory T cells. J Immunol 177 (2006) 40-44
28. Lewkowich I.P., Herman N.S., Schleifer K.W., Dance M.P., Chen B.L., Dienger K.M., et al. CD4+CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J Exp Med 202 (2005) 1549-1561
29. Serra P., Amrani A., Yamanouchi J., Han B., Thiessen S., Utsugi T., et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity 19 (2003) 877-889
30. Tadokoro C.E., Shakhar G., Shen S., Ding Y., Lino A.C., Maraver A., et al. Regulatory T cells inhibit stable contacts between CD4+ T cells and dendritic cells in vivo. J Exp Med 203 (2006) 505-511
31. Tang Q., Adams J.Y., Tooley A.J., Bi M., Fife B.T., Serra P., et al. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol 7 (2006) 83-92
32. Adorini L., Giarratana N., and Penna G. Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 16 (2004) 127-134
33. Morelli A.E., and Thomson A.W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 7 (2007) 610-621
34. Allison A.C. Immunosuppressive drugs: The first 50 years and a glance forward. Immunopharmacology 47 (2004) 63-83
35. Lagaraine C., and Lebranchu Y. Effects of immunosuppressive drugs on dendritic cells and tolerance induction. Transplantation 75 (2003) 37S-42S
36. Woltman A.M., and van Kooten C. Functional modulation of dendritic cells to suppress adaptive immune responses. J Leukoc Biol 73 (2003) 428-441
37. Hackstein H., and Thomson A.W. Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 4 (2004) 24-34
38. Vieira P.L., Kalinski P., Wierenga E.A., Kapsenberg M.L., and de Jong E.C. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential. J Immunol 161 (1998) 5245-5251
39. Matasic R., Dietz A.B., and Vuk-Pavlovic S. Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J Leukoc Biol 66 (1999) 909-914
40. Piemonti L., Monti P., Allavena P., Sironi M., Soldini L., Leone B.E., et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 162 (1999) 6473-6481
41. Woltman A.M., de Fijter J.W., Kamerling S.W., Paul L.C., Daha M.R., and van Kooten C. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur J Immunol 30 (2000) 1807-1812
42. Mehling A., Grabbe S., Voskort M., Schwarz T., Luger T.A., and Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 165 (2000) 2374-2381
43. Colic M., Stojic-Vukanic Z., Pavlovic B., Jandric D., and Stefanoska I. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 134 (2003) 63-69
44. Woltman A.M., de Fijter J.W., Kamerling S.W., van Der Kooij S.W., Paul L.C., Daha M.R., and van Kooten C. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 98 (2001) 174-180
45. Hackstein H., Taner T., Zahorchak A.F., Morelli A.E., Logar A.J., Gessner A., and Thomson A.W. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101 (2003) 4457-4463
46. Taner T., Hackstein H., Wang Z., Morelli A.E., and Thomson A.W. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce ag-specific T cell regulation and prolong graft survival. Am J Transplant 5 (2005) 228-236
47. Lee J.I., Ganster R.W., Geller D.A., Burckart G.J., Thomson A.W., and Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: Association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 68 (1999) 1255-1263
48. Szabo G., Gavala C., and Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J Investig Med 49 (2001) 442-449
49. Contreras J.L., Wang P.X., Eckhoff D.E., Lobashevsky A.L., Asiedu C., Frenette L., et al. Peritransplant tolerance induction with anti-CD3-immunotoxin: A matter of proinflammatory cytokine control. Transplantation 65 (1998) 1159-1169
50. Thomas J.M., Contreras J.L., Jiang X.L., Eckhoff D.E., Wang P.X., Hubbard W.J., et al. Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 68 (1999) 1660-1673
51. Thomas J.M., Hubbard W.J., Sooudi S.K., and Thomas F.T. STEALTH matters: A novel paradigm of durable primate allograft tolerance. Immunol Rev 183 (2001) 223-233
52. Matasic R., Dietz A.B., and Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 101 (2000) 53-60
53. Hackstein H., Morelli A.E., Larregina A.T., Ganster R.W., Papworth G.D., Logar A.J., et al. Aspirin inhibits in vitro maturation and in vivo immunostimulatory function of murine myeloid dendritic cells. J Immunol 166 (2001) 7053-7062
54. Buckland M., Jago C., Fazekesova H., George A., Lechler R., and Lombardi G. Aspirin modified dendritic cells are potent inducers of allo-specific regulatory T-cells. Int Immunopharmacol 6 (2006) 1895-1901
55. Buckland M., Jago C.B., Fazekasova H., Scott K., Tan P.H., George A.J., et al. Aspirin-treated human DCs up-regulate ILT-3 and induce hyporesponsiveness and regulatory activity in responder T cells. Am J Transplant 6 (2006) 2046-2059
56. Millard A.L., Mertes P.M., Ittelet D., Villard F., Jeannesson P., and Bernard J. Butyrate affects differentiation, maturation and function of human monocyte-derived dendritic cells and macrophages. Clin Exp Immunol 130 (2002) 245-255
57. Svajger U., Vidmar A., and Jeras M. Niflumic acid renders dendritic cells tolerogenic and up-regulates inhibitory molecules ILT3 and ILT4. Int Immunopharmacol 8 (2008) 997-1005
58. Verhasselt V., Vanden Berghe W., Vanderheyde N., Willems F., Haegeman G., and Goldman M. N-acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level: Association with NF-kappaB inhibition. J Immunol 162 (1999) 2569-2574
59. Buckland M., and Lombardi G. Aspirin and the Induction of Tolerance by Dendritic Cells. Handb Exp Pharmacol 188 (2009) 197-213
60. 3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 167 (2001) 1945-1953
61. Izawa A., Sayegh M.H., and Chandraker A. The antagonism of calcineurin inhibitors and costimulatory blockers: Fact or fiction?. Transplant Proc 36 2 Suppl (2004) 570S-573S
62. Saemann M.D., Kelemen P., Bohmig G.A., Horl W.H., and Zlabinger G.J. Hyporesponsiveness in alloreactive T-cells by NF-kappaB inhibitor-treated dendritic cells: Resistance to calcineurin inhibition. Am J Transplant 4 (2004) 1448-1458
63. Game D.S., Hernandez-Fuentes M.P., and Lechler R.I. Everolimus and basiliximab permit suppression by human CD4CD25 cells in vitro. Am J Transplant 5 (2005) 454-464
64. Trembleau S., Germann T., Gately M.K., and Adorini L. The role of IL-12 in the induction of organ-specific autoimmune diseases. Immunol Today 16 (1995) 383-386
65. Bonizzi G., and Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25 (2004) 280-288
66. Martin E., O'Sullivan B., Low P., and Thomas R. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18 (2003) 155-157
67. Scheinman R.I., Cogswell P.C., Lofquist A.K., and Baldwin Jr. A.S. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-285
68. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270 (1995) 286-290
69. Giarratana N., Penna G., Amuchastegui S., Mariani R., Daniel K.C., and Adorini L. A vitamin D analog downregulates proinflammatory chemokine production by pancreatic islets inhibiting T cell recruitment and type 1 diabetes development. J Immunol 173 (2004) 2280-2287
70. Dong X., Craig T.A., Xing N., Bachman L.A., Paya C.V., Weih F., et al. Direct transcriptional regulation of RelB by 1alpha,25-dihydroxyvitamin D3 and its analogs: Physiologic and therapeutic implications for dendritic cell function. J Biol Chem 278 (2003) 49378-49385
71. Penna G., Amuchastegui S., Giarratana N., Daniel K.C., Vulcano M., Sozzani S., and Adorini L. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol 178 (2007) 145-153
72. Deluca H.F., and Cantorna M.T. Vitamin D: Its role and uses in immunology. FASEB J 15 (2001) 2579-2585
73. Mathieu C., and Adorini L. The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med 8 (2002) 174-179
74. Adorini L. Immunomodulatory effects of vitamin D receptor ligands in autoimmune diseases. Int Immunopharmacol 2 (2002) 1017-1028
75. Griffin M.D., Xing N., and Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu Rev Nutr 23 (2003) 117-145
76. Adorini L., and Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 4 (2008) 404-412
77. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res 164 (2003) 29-42
78. Penna G., and Adorini L. 1,25-Dihydroxyvitamin D3 inhibits differentiation, maturation, activation and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164 (2000) 2405-2411
79. Piemonti L., Monti P., Sironi M., Fraticelli P., Leone B.E., Dal Cin E., et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 164 (2000) 4443-4451
80. Griffin M.D., Lutz W.H., Phan V.A., Bachman L.A., McKean D.J., and Kumar R. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 270 (2000) 701-708
81. Berer A., Stockl J., Majdic O., Wagner T., Kollars M., Lechner K., et al. 1,25-Dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol 28 (2000) 575-583
82. Canning M.O., Grotenhuis K., de Wit H., Ruwhof C., and Drexhage H.A. 1-Alpha,25-dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 145 (2001) 351-357
83. van Halteren A.G., van Etten E., de Jong E.C., Bouillon R., Roep B.O., and Mathieu C. Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D(3). Diabetes 51 (2002) 2119-2125
84. Széles L., Keresztes G., Töröcsik D., Balajthy Z., Krenács L., Póliska S., et al. 1,25-Dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol 182 (2009) 2074-2083
85. Hewison M., Freeman L., Hughes S.V., Evans K.N., Bland R., Eliopoulos A.G., et al. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J Immunol 170 (2003) 5382-5390
86. Sigmundsdottir H., Pan J., Debes G.F., Alt C., Habtezion A., Soler D., and Butcher E.C. DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27. Nat Immunol 8 (2007) 285-293
87. Griffin M.D., Lutz W., Phan V.A., Bachman L.A., McKean D.J., and Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 98 (2001) 6800-6805
88. Chen S., Sims G.P., Chen X.X., Gu Y.Y., and Lipsky P.E. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179 (2007) 1634-1647
89. Chen X., and Jensen P.E. Cutting edge: Primary B lymphocytes preferentially expand allogeneic FoxP3+ CD4 T cells. J Immunol 179 (2007) 2046-2050
90. Adorini L. 1,25-Dihydroxyvitamin D3 analogs as potential therapies in transplantation. Curr Opin Investig Drugs 3 (2002) 1458-1463
91. Dhodapkar M.V., Steinman R.M., Krasovsky J., Munz C., and Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193 (2001) 233-238
92. 3 analog enhances regulatory T cells and arrests autoimmune diabetes in NOD mice. Diabetes 51 (2002) 1367-1374
93. Gorman S., Kuritzky L.A., Judge M.A., Dixon K.M., McGlade J.P., Mason R.S., et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 179 (2007) 6273-6283
94. Daniel C., Sartory N.A., Zahn N., Radeke H.H., and Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 324 (2008) 23-33
95. Barrat F.J., Cua D.J., Boonstra A., Richards D.F., Crain C., Savelkoul H.F., et al. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195 (2002) 603-616
96. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., de Vries J.E., and Roncarolo M.G. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389 (1997) 737-742
97. Klotz L., Dani I., Edenhofer F., Nolden L., Evert B., Paul B., et al. Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy. J Immunol 178 (2007) 2122-2131
98. Wohlfert E.A., Nichols F.C., Nevius E., and Clark R.B. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: Enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 178 (2007) 4129-4135
99. Hontecillas R., and Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 178 (2007) 2940-2949
100. Yokoyama W.M. What goes up must come down: The emerging spectrum of inhibitory receptors. J Exp Med 186 (1997) 1803-1808
101. Colonna M., Nakajima H., Navarro F., and Lopez-Botet M. A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells. J Leukoc Biol 66 (1999) 375-381
102. Ravetch J.V., and Lanier L.L. Immune inhibitory receptors. Science 290 (2000) 84-90
103. Cella M., Dohring C., Samaridis J., Dessing M., Brockhaus M., Lanzavecchia A., and Colonna M. A novel inhibitory receptor (ILT3) expressed on monocytes, macrophages, and dendritic cells involved in antigen processing. J Exp Med 185 (1997) 1743-1751
104. Chang C.C., Ciubotariu R., Manavalan J.S., Yuan J., Colovai A.I., Piazza F., et al. Tolerization of dendritic cells by T(S) cells: The crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 3 (2002) 237-248
105. Suciu-Foca N., and Cortesini R. Central role of ILT3 in the T suppressor cell cascade. Cell Immunol 248 (2007) 59-63
106. Manavalan J.S., Kim-Schulze S., Scotto L., Naiyer A.J., Vlad G., Colombo P.C., et al. Alloantigen specific CD8+CD28- FOXP3+ T suppressor cells induce ILT3+ ILT4+ tolerogenic endothelial cells, inhibiting alloreactivity. Int Immunol 16 (2004) 1055-1098
107. Takai T., and Ono M. Activating and inhibitory nature of the murine paired immunoglobulin-like receptor family. Immunol Rev 181 (2001) 215-222
108. Liu J., Liu Z., Witkowski P., Vlad G., Manavalan J.S., Scotto L., et al. Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection. Transpl Immunol 13 (2004) 239-247
109. Cortesini R. Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3). JOPe 8 (2007) 697-703
110. Vlad G., Cortesini R., and Suciu-Foca N. CD8(+) T suppressor cells and the ILT3 master switch. Hum Immunol 69 (2008) 681-686
111. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., and Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5 (1999) 919-923
112. Penna G., Sozzani S., and Adorini L. Cutting edge: Selective usage of chemokine receptors by plasmacytoid dendritic cells. J Immunol 167 (2001) 1862-1866
113. Penna G., Roncari A., Colonna M., and Adorini L. 1,25 Dihydroxyvitamin D3 upregulates the expression of the inhibitory receptor ILT3 on dendritic cells. Minerva Biotec 14 (2002) 71 (Abstract)
114. Gilliet M., and Liu Y.J. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 195 (2002) 695-704
115. Penna G., Roncari A., Amuchastegui S., Daniel K.C., Berti E., Colonna M., and Adorini L. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3. Blood 106 (2005) 3490-3497
116. Manavalan J.S., Rossi P.C., Vlad G., Piazza F., Yarilina A., Cortesini R., et al. High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells. Transpl Immunol 11 (2003) 245-248
117. Xing N., ML L.M., Bachman L.A., McKean D.J., Kumar R., and Griffin M.D. Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways. Biochem Biophys Res Commun 297 (2002) 645-652
118. Fedoric B., and Krishnan R. Rapamycin downregulates the inhibitory receptors ILT2, ILT3, ILT4 on human dendritic cells and yet induces T cell hyporesponsiveness independent of FoxP3 induction. Immunol Lett 120 (2008) 49-56
119. Turnquist H.R., Raimondi G., Zahorchak A.F., Fischer R.T., Wang Z., and Thomson A.W. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 178 (2007) 7018-7031
120. Xie J.H., Nomura N., Lu M., Chen S.L., Koch G.E., Weng Y., et al. Antibody-mediated blockade of the CXCR3 chemokine receptor results in diminished recruitment of T helper 1 cells into sites of inflammation. J Leukoc Biol 73 (2003) 771-780
121. Frigerio S., Junt T., Lu B., Gerard C., Zumsteg U., Hollander G.A., and Piali L. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 8 (2002) 1414-1420
122. Iellem A., Mariani M., Lang R., Recalde H., Panina-Bordignon P., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194 (2001) 847-853
123. Giarratana N., Penna G., and Adorini L. Animal models of spontaneous autoimmune disease: Type 1 diabetes in the nonobese diabetic mouse. Methods Mol Biol 380 (2007) 285-312
124. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
125. Penna G., Vulcano M., Roncari A., Facchetti F., Sozzani S., and Adorini L. Differential chemokine production by myeloid and plasmacytoid dendritic cells. J Immunol 169 (2002) 6673-6676
126. Steinman R.M., and Hemmi H. Dendritic cells: Translating innate to adaptive immunity. Curr Top Microbiol Immunol 311 (2006) 17-58
127. Li Q., and Verma I.M. NF-kappaB regulation in the immune system. Nat Rev Immunol 2 (2002) 725-743
128. + plasmacytoid dendritic cells. Curr Drug Metab 8 (2007) 209-216